2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 803

Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus?
Abstract Number: 804

Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients
Abstract Number: 805

Interferon Activity in Early and Established SLE: Interferon Score Is Lower in Early Disease and Not Seen without Antibodies to Extractable Nuclear Antigens
Abstract Number: 806

STAT1 Activation Promotes TLR8 Overexpression and Facilitates Mirokine Signaling Via Exosomes Containing a Mir-21 Endogenous Ligand: A Novel Innate Inflammatory Pathway in Systemic Lupus Erythematosus
Abstract Number: 807

High Levels of Serum IFN-Alpha Mark a Subgroup of SLE Patients with Distinct Immunophenotypic Features and Hyperresponsiveness to Toll-like Receptor Stimulation
Abstract Number: 808

Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE
Abstract Number: 809

Patients with SLE Who Are Anti-Factor Xa IgG Positive Are Less Likely to Have Atherosclerotic Plaque
Abstract Number: 810

Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity
Abstract Number: 811

Antibody Response to Periodontogenic Bacterium Aggregatibacter Actinomycetemcomitans and Lupus
Abstract Number: 812

SLAMF3 Mediated Co-Stimulation Promotes Activation of the IL-2/IL-2R/STAT5 Pathway and Regulatory T Cells Differentiation in Human Naïve CD4+ T Cells – Implications for SLE
Abstract Number: 813

Expression of Inducible Costimulator Ligand (ICOSL) on CD4+ T Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 814

Lupus Drives Atherosclerosis through CD4+CXCR3+ T Cells and Plasmacytoid Dendritic Cells
Abstract Number: 815

Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus
Abstract Number: 816

Incomplete Tolerance in Anergic B Cells in SLE: T Helper Signals Restore B Cell Receptor Signaling in Autoreactive Anergic B Cells By Upregulating CD45 Phosphatase Activity
Abstract Number: 817

Circulating Endothelial Cell (CEC) and CEC-Bound C4d Levels As Biomarkers of Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].